12.9: Chapter Summary

Quality and Regulatory Compliance in Bioscience · LibreTexts

0%

Contents

    Text

    Size
    100%
    Theme
    Typeface
    Line length
    Spacing

    Read aloud

    How

    Speed: 1×
    Light up
    Highlight

    Symbols: Mulberry Symbols, © 2018–2026 Steve Lee, CC BY-SA 4.0 (licence, the set), the site's own copies.

    From LibreTexts, under CC BY-SA 4.0, as the source states it; its equations are written in TeX, which the PDF shows typeset. This page at LibreTexts.

    12.9: Chapter Summary

    A medicine moves from discovery through nonclinical and clinical studies, FDA review, and oversight after approval. The evidence at each stage helps teams decide whether to continue, change direction, or stop. An IND supports covered research in people. Marketing applications ask FDA to evaluate the evidence, labeling, and manufacturing controls for a proposed product and use.

    Quality assurance supports consistent work through procedures, training, and oversight. Quality control checks materials and products against requirements. After approval, complaint patterns and safety reports can prompt investigations. Traceability helps the team identify affected lots and contact the people who received them. The McNeil case shows why timely investigations, management follow-through, and checks on corrective actions matter.

    Key Terms

    active pharmaceutical ingredient (API)

    drug product

    therapeutic biological product

    biopharmaceutical

    quality assurance (QA)

    quality control (QC)

    high-throughput screening (HTS)

    ADME

    toxicology

    investigational new drug application (IND)

    good clinical practice (GCP)

    institutional review board (IRB)

    informed consent

    randomization

    masking

    bioresearch monitoring (BIMO)

    new drug application (NDA)

    biologics license application (BLA)

    abbreviated new drug application (ANDA)

    bioavailability

    bioequivalence

    priority review

    orphan drug designation

    accelerated approval

    surrogate endpoint

    fast track

    breakthrough therapy designation

    tentative approval

    cross-contamination

    cleaning validation

    postmarket surveillance

    traceability

    Form FDA 483

    warning letter

    consent decree

    corrective and preventive actions (CAPA)

    continuous improvement

    current good manufacturing practice (cGMP)

     

    Review Questions

    1. How do a drug substance and a finished drug product differ?

    2. What does ADME stand for, and what does it help researchers understand?

    3. What three types of information does an IND provide?

    4. What questions do Phases 1, 2, and 3 generally address?

    5. How do informed consent and IRB review protect participants?

    6. What does FDA evaluate in an NDA or BLA? How does an ANDA use evidence about a reference drug?

    7. How do priority review, accelerated approval, and orphan designation differ?

    8. How do supplier controls and cleaning validation help prevent contamination?

    9. How can traceability help a manufacturer define the scope of a recall?

    10. How do Class I, II, and III recalls differ?

    11. What are the purposes of Form FDA 483, a warning letter, and a consent decree?

    Apply Your Understanding

    1. A candidate enzyme shows promising activity in cultured cells. A manager wants to begin giving it to volunteers immediately. Identify the additional evidence, manufacturing information, and participant protections that should be addressed before a covered clinical investigation begins.

    2. A team plans to transfer production of a clinical study material to a larger vessel. Explain why scale-up is more than a change in volume. What information could help determine whether material made at the new scale remains suitable for the study?

    3. A hypothetical candidate improves a laboratory marker but causes frequent severe side effects. Explain why the marker alone does not settle the benefit-risk question. What additional information would help interpret the findings?

    4. A manufacturer detects residue from a previous product after cleaning shared equipment. The next batch passes its final tests. Explain why those tests alone do not settle the concern and identify evidence needed before a disposition decision.

    5. An inspection ends with one Form FDA 483 observation about incomplete investigations. Management calls it minor because there is only one observation. Explain why this reasoning is inadequate and propose a response with evidence, actions, responsibilities, and effectiveness checks.

    6. Using the documented McNeil case, identify two points where stronger investigation, communication, or management oversight could have improved the response. Propose two measures that would help evaluate whether complaint handling is improving.


    This page titled 12.9: Chapter Summary was last modified on Thu, 05 Nov 2026 12:43:41 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.